Page last updated: 2024-11-02

oxyphenbutazone and Fibrous Dysplasia of Bone

oxyphenbutazone has been researched along with Fibrous Dysplasia of Bone in 1 studies

Oxyphenbutazone: A non-steroidal anti-inflammatory drug. Oxyphenbutazone eyedrops have been used abroad in the management of postoperative ocular inflammation, superficial eye injuries, and episcleritis. (From AMA, Drug Evaluations Annual, 1994, p2000) It had been used by mouth in rheumatic disorders such as ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis but such use is no longer considered justified owing to the risk of severe hematological adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p27)
oxyphenbutazone : A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome.

Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cohrs, U1
Hauswaldt, C1
Hunstein, W1

Other Studies

1 other study available for oxyphenbutazone and Fibrous Dysplasia of Bone

ArticleYear
[The modification of experimental bone marrow fibrosis after repeated administration of foreign proteins by antiphlogistics and prednisolone acetate].
    Blut, 1969, Volume: 19, Issue:7

    Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents; Blood Cell Count; Blood Platelets; Body Weight; Bone

1969